Benzamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]- manufacturers
- SBI-993
-
-
2026-07-15
- CAS:2073059-82-0
- Purity:
- Supply Ability: 10g
|
| | Benzamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]- Basic information |
| | Benzamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]- Chemical Properties |
| density | 1.352±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 100 mg/mL (220.98 mM; ultrasonic and warming and heat to 60°C) | | form | Solid | | pka | 7.55±0.50(Predicted) | | color | White to off-white |
| | Benzamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]- Usage And Synthesis |
| Uses | SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA[1]. | | in vivo | SBI-993 (50 mg/kg; s.c.; daily; for 7 days) treatment reduces the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. SBI-993 also reduces Txnip and Arrdc4 expression. And ccupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters is reduced in liver by SBI-993[1].
SBI-993 improves insulin signaling in both muscle and liver following an acute insulin challenge[1]. | Animal Model: | Mice are fed a 60% high-fat diet (HFD)[1] | | Dosage: | 50 mg/kg
| | Administration: | s.c.; daily; for 7 days | | Result: | Reduced the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. |
| | References | [1] Byungyong Ahn, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79. DOI:10.1172/JCI87382 |
| | Benzamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[[2-(4-morpholinyl)-2-oxoethyl]amino]- Preparation Products And Raw materials |
|